Group 1 - Benitec Biopharma Limited (BNTC) is currently outperforming the Medical sector, gaining approximately 14.1% year-to-date, while the sector has lost an average of 3.5% [4] - The Zacks Consensus Estimate for BNTC's full-year earnings has increased by 57.5% in the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4] - Benitec Biopharma Limited holds a Zacks Rank of 2 (Buy), suggesting a favorable investment opportunity based on earnings estimates and revisions [3] Group 2 - Benitec Biopharma Limited is part of the Medical - Biomedical and Genetics industry, which consists of 508 companies and currently ranks 84 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has experienced an average loss of 3.3% year-to-date, further highlighting BNTC's strong performance relative to its peers [6] - Concentra Group (CON), another Medical stock, has also outperformed the sector with a return of 8.9% year-to-date, and it holds a Zacks Rank of 2 (Buy) [5][7]